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Abstract
Purpose This study investigated metabolic benefits of protein hydrolysates from the macroalgae Palmaria palmata, previ-
ously shown to inhibit dipeptidylpeptidase-4 (DPP-4) activity in vitro.
Methods Previously, Alcalase/Flavourzyme-produced P. palmata protein hydrolysate (PPPH) improved glycaemia and 
insulin production in streptozotocin-induced diabetic mice. Here the PPPH, was compared to alternative Alcalase, bromelain 
and Promod-derived hydrolysates and an unhydrolysed control. All PPPH’s underwent simulated gastrointestinal digestion 
(SGID) to establish oral bioavailability. PPPH’s and their SGID counterparts were tested in pancreatic, clonal BRIN-BD11 
cells to assess their insulinotropic effect and associated intracellular mechanisms. PPPH actions on the incretin effect were 
assessed via measurement of DPP-4 activity, coupled with GLP-1 and GIP release from GLUTag and STC-1 cells, respec-
tively. Acute in vivo effects of Alcalase/Flavourzyme PPPH administration on glucose tolerance and satiety were assessed 
in overnight-fasted mice.
Results PPPH’s (0.02–2.5 mg/ml) elicited varying insulinotropic effects (p < 0.05–0.001). SGID of the unhydrolysed protein 
control, bromelain and Promod PPPH’s retained, or improved, bioactivity regarding insulin secretion, DPP-4 inhibition and 
GIP release. Insulinotropic effects were retained for all SGID-hydrolysates at higher PPPH concentrations. DPP-4 inhibitory 
effects were confirmed for all PPPH’s and SGID counterparts (p < 0.05–0.001). PPPH’s were shown to directly influence 
the incretin effect via upregulated GLP-1 and GIP (p < 0.01–0.001) secretion in vitro, largely retained after SGID. Alcalase/
Flavourzyme PPPH produced the greatest elevation in cAMP (p < 0.001, 1.7-fold), which was fully retained post-SGID. 
This hydrolysate elicited elevations in intracellular calcium (p < 0.01) and membrane potential (p < 0.001). In acute in vivo 
settings, Alcalase/Flavourzyme PPPH improved glucose tolerance (p < 0.01–0.001) and satiety (p < 0.05–0.001).
Conclusion Bioavailable PPPH peptides may be useful for the management of T2DM and obesity.
Keywords Antidiabetic · Dipeptidylpeptidase-4 · Dulse · Incretin secretion · Palmaria palmata · Protein hydrolysate · Type 
2 diabetes
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Introduction
Type 2 diabetes mellitus (T2DM) is a metabolic disorder 
of complex aetiology characterised by a deficiency, and/
or dysfunction of endogenous insulin and glucagon pro-
duction [1]. In diabetes, loss of insulin-producing pancre-
atic beta-cell mass [2], is accompanied by dysfunction of 
glucagon-producing alpha cells, which fail to respond to the 
normal suppressive effects of glucose and insulin, leading 
to hyperglucagonaemia [3]. Best-estimates state that there 
are around 463 million adults globally living with diabetes, 
projected to rise to 700 million by 2045 [4], with T2DM 
representing ~ 90% of cases. The economic burden of dia-
betes on global healthcare systems is considerable, with a 
minimum of $760 billion USD attributed to spending on the 
disease in 2019, equating to 10% of global adult healthcare 
costs [4]. An important factor in this spending arises from 
costs amassed from treatment of microvascular (retinopathy, 
nephropathy, and neuropathy) and macrovascular (coronary 
artery disease, stroke, and peripheral vascular disease) com-
plications [5]. Preventative strategies, coupled with earlier 
diagnosis and novel treatments, have the potential to reduce 
the occurrence of these complications [6].
Lifestyle interventions such as increased physical activity 
and improved, nutritionally balanced diets are considered 
first-line options in the prevention and treatment of T2DM 
[7, 8]. While high-quality dietary protein is an integral part 
of any such diet [9], it has also been established that a high-
protein diet can lower postprandial blood glucose in T2DM 
and improve overall glucose and lipid metabolism [10, 11]. 
Beyond dietary protein, protein hydrolysates, peptides and 
single amino acids can beneficially regulate glycaemia, with 
the magnitude of response differing significantly depend-
ing on the primary sequence of peptides and specific amino 
acids generated following digestion [12, 13].
Mechanisms determining glycaemic improvements of 
various protein hydrolysates have been established, high-
lighting the importance of inhibitory actions on the ubiqui-
tous enzyme dipeptidylpeptidase-4 (DPP-4) [14–18]. DPP-4 
inhibition has become a staple of diabetes management, with 
a plethora of drugs now available since the approval of sit-
agliptin (Januvia®) in 2006 [19]. Success of DPP-4 inhibi-
tion lies in the preservation of the “incretin effect”, which 
promotes a rise in plasma insulin following food intake [20]. 
The rise in plasma insulin not only reflects a response to 
increased postprandial glucose, but approximately 50% of 
the overall insulinotropic response is attributed to the release 
of two gut-derived hormones, namely: glucagon-like peptide 
1 (GLP-1) and glucose-dependent insulinotropic polypeptide 
(GIP) [20]. Both GLP-1 and GIP are inactivated following 
N-terminal dipeptide removal by DPP-4 [19]. Furthermore, 
DPP-4 resistant GLP-1 receptor agonists (incretin mimetics) 
have also been developed and are widely prescribed for 
T2DM management [21–23].
It has recently been uncovered that, beyond DPP-4 inhibi-
tion, protein hydrolysates from underutilised marine sources, 
such as blue whiting, boarfish and salmon skin, can directly 
influence glycaemia through improved insulin production 
and secretion coupled with upregulated GLP-1 secretion 
in both in vitro [24–26] and in vivo settings [25, 27]. The 
present study has sought to establish whether crude hydro-
lysates of the macroalgae Palmaria palmata can replicate the 
effects of piscine-derived protein hydrolysates.
P. palmata (dulse) has become popular as a foodstuff due 
to its relatively high protein content [28], in addition to being 
a potential source of biofunctional proteinaceous and antioxi-
dant ingredients [29–31]. Notably, both crude hydrolysates of 
P. palmata [32] and isolated peptides from this source have 
demonstrated an ability to inhibit DPP-4 in vitro [33]. Further-
more, twice daily, chronic administration of a crude P. palmata 
protein hydrolysate, Alcalase/Flavourzyme PPPH, has been 
shown to improve glycaemic control in streptozotocin-induced 
diabetic mice [34]. Thus, the present study aims to employ a 
number of established screening methods to uncover the spe-
cific mechanisms responsible for the positive glycaemic effects 




H-Gly-Pro-AMC (7-amino-4–methyl coumarin) and 
Diprotin A were obtained from Bachem Feinchemikalien 
(Bubendorf, Switzerland). Promod 144 MG provided by 
Biocatalysts Ltd. (Cardiff, Wales, UK). HPLC grade water 
and acetonitrile from VWR International (Dublin, Ireland) 
and trinitrobenzenesulphonic acid (TNBS) reagent was from 
Medical Supply Co Ltd. (Dublin, Ireland). Calcium chloride 
dihydrate  (CaCl2 ×  2H2O), d-glucose, HEPES, hydrochloric 
acid (HCl), magnesium sulphate  (MgSO4 ×  7H2O), potas-
sium dihydrogen orthophosphate  (KH2PO4), potassium 
chloride (KCl), sodium bicarbonate  (NaHCO3) and sodium 
chloride (NaCl) were purchased from BDH Chemicals Ltd. 
(Poole, Dorset, UK). Foetal bovine serum (FBS), Hank’s 
buffered saline solution (HBSS 10X stock), penicillin–strep-
tomycin (0.1 g/l), RPMI-1640 culture media, Dulbecco’s 
modified Eagle’s medium (DMEM)-containing high glucose 
and trypsin/EDTA (10X) were obtained from Gibco Life 
Technologies Ltd. (Paisley, Strathclyde, UK). Radio-labelled 
sodium iodide  (Na125I, IMS 100 mCi/ml stock) was from 
Perkin Elmer (Buckinghamshire, UK). Rat insulin stand-
ard was from Novo Industria, Copenhagen, Denmark. All 
other reagents including DPP-4, from porcine kidney (≥ 10 
units/mg protein), Alcalase® 2.4 L and Flavourzyme® 500 
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L supplied by Sigma Chemical Company Ltd. (Wicklow, 
Ireland). Air-dried milled (5 mm) P. palmata sample was 
purchased from Irish Seaweeds Ltd., Belfast, Co. Antrim, 
N. Ireland. The macroalgae was further milled with a Cyclo-
tec™ Mill (1 mm screen, FOSS Tecator AB, Hoganas, Swe-
den) and stored at RT.
Preparation of crude aqueous soluble protein 
extracts
Crude aqueous and alkaline soluble protein extracts were 
prepared using the method described previously [32]. Milled 
P. palmata powder was suspended at a mass:volume ratio of 
1:20 ((w/v), 1 kg:20.0 l) and gently agitated at room temper-
ature for 3 h. The supernatant containing the aqueous soluble 
protein was acquired following centrifugation at 4,190 × g 
(Sorvall RC6 Plus, Fisher Scientific, Dublin, Ireland) for 
15 min at RT. The pellet was resuspended in 0.12 M NaOH 
(1:15 (w/v)) and gently agitated for 1 h at RT and superna-
tant containing the alkaline soluble protein was acquired 
following centrifugation. The pellet was subjected to a sec-
ond alkaline extraction, and both supernatants combined. 
A double isoelectric precipitation step was utilised to semi-
purified and concentrated aqueous (pH 2.5) and alkaline (pH 
4.0) soluble protein components. The precipitated protein 
pellets obtained following the second isoelectric precipita-
tion were resuspended in  dH2O to a protein concentration 
of ~ 2.4% (w/v) and combined. Protein concentration was 
determined by the modified Lowry protein quantification 
method as described previously [35]. Samples were analysed 
in triplicate.
Enzymatic hydrolysis of macroalgal proteins 
and simulated gastrointestinal digestion
Macroalgal protein was hydrolysed as described previously 
[32]. A 2% (w/v) protein solution was preheated to 50°C and 
adjusted to pH 7.0 and hydrolysed with Alcalase 2.4 L, Alca-
lase 2.4 L and Flavourzyme 500 L, bromelain and Promod 
144 MG at an enzyme:substrate (E:S) ratio of 1:100 (w/w 
or v/w) for 4 h at 50°C. The reaction was maintained at pH 
7.0 using a pH–stat (842 Titrando, Metrohm, Switzerland) 
and enzyme inactivated by heating at 90°C for 20 min. A 
control protein sample, containing no proteolytic enzyme, 
was treated in the same manner. All samples were subse-
quently freeze–dried (FreeZone 18L, Labconco, MO, USA) 
and stored at − 20 °C.
To assess oral bioavailability, PPPH’s were subjected 
to simulated gastrointestinal digestion (SGID), described 
previously [36]. In brief, unhydrolysed protein controls and 
hydrolysates were diluted to 2.0% (w/v) protein in water 
and incubated at 37°C and pH 2 for 90 min with pepsin at 
an E:S of 1:40 (w/w). The samples were adjusted to pH 7 
and subjected to heat inactivation at 90°C for 20 min. The 
samples were incubated for a further 150 min at 37 °C with 
Corolase PP (E:S of 1% (w/w)). SGID samples were heat 
inactivated and all samples were subsequently freeze-dried 
and stored at − 20°C.
Physicochemical characterisation of PPPH
The molecular mass distribution profile of the hydrolysates 
and their SGID samples were determined by gel permea-
tion–high-performance liquid chromatography (GP-HPLC) 
as described previously [37]. The amino nitrogen content of 
PPPH was estimated by the TNBS method with absorbance 
readings taken at 350 nm [38]. Samples were analysed in 
triplicate.
Insulin secretion studies in clonal pancreatic cells
Insulinotropic effects of PPPH and SGID samples were 
measured in  vitro using clonal pancreatic BRIN-BD11 
cells [39]. BRIN-BD11 cells (1.5 ×  105 cells/well) were 
incubated for 20 min with a range of PPPH concentrations 
(0.039–2.5 mg/ml) in the presence of 5.6 mM glucose at 
37°C. Following incubation, supernatant (900 µL) was with-
drawn and frozen at − 20°C until required. Insulin was quan-
tified using a dextran-coated charcoal radioimmunoassay 
(RIA), using crystalline rat insulin standard, guinea-pig 
anti-porcine antiserum (1:30,000 dilution) and 125I-bovine 
standard (10,000 cpm), described previously [40]. The con-
centration of insulin in each sample was determined in dupli-
cate from the prepared insulin standard curve ranging from 
0.039–20 ng/ml.
Cellular toxicity via MTT assay
To determine cytotoxicity of PPPH and SGID samples on 
BRIN-BD11 cells, the MTT (3-(4,5-Dimethylthiazol-2-yl)-
2,5-Diphenyltetrazolium Bromide) assay was employed. A 
fixed dose of PPPH was prepared in Krebs Ringer bicar-
bonate buffer (KRBB) buffer supplemented with 5.6 or 
16.7  mM glucose. Upon completion of co-incubation, 
KRBB was removed and cells washed with HBSS. Growth 
media (100 μl) was added to each well of a 96 well plate and 
further supplemented with 20 μl of MTT solution (5 mg/ml 
stock). Plates were incubated for 2 h in a modified atmos-
phere (95%  O2, 5%  CO2) tissue culture incubator at 37°C. 
MTT/growth media was aspirated and washed for a final 
time with HBSS. The formazan crystals developed were then 
dissolved using 100 μl of DMSO and the plate agitated at 
RT for 5 min. Plates were read on a spectrophotometer with 
absorbance set at 570 nm.
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Quantification of DPP‑4 inhibition
DPP-4 inhibition was determined as described previously 
[33]. Activity was expressed as  IC50 values for three inde-
pendent replicates (n = 3). Diprotin A was used as a positive 
control.
In vitro GLP‑1 secretion from GLUTag cells and GIP 
secretion from STC‑1 cells
In vitro effects of the PPPH and the SGID samples on GLP-1 
secretion were measured using the murine enteroendocrine 
GLUTag cell line [41], kindly gifted by Prof. Fiona Grib-
ble/Daniel Drucker. Cells were cultured in high glucose 
(25 mM) Dulbecco’s Modified Eagle’s Medium (without 
glutamine), as described previously [42]. Cells were seeded 
into 24-well plates (1.5 ×  105 cells/well) attaching over 36 h 
at 37°C. Following a pre-incubation step (1.1 mM glucose 
solution in KRBB for 40 min at 37°C), cells were incubated 
with the PPPH and SGID samples (2.5 mg/ml) prepared in 
2 mM glucose followed by 2 h incubation at 37°C. There-
after, 800 µl of supernatant was collected and subsequently 
used to measure total GLP-1 release by ELISA (Millipore, 
Hertfordshire, UK) as per manufacturer’s protocol.
STC-1 cells differentiate by secreting satiety and glucose 
homeostatic hormones such as CCK, GIP, PYY, GLP-1 and 
GLP-2 [43]. The experimental procedure was similar to 
the GLUTag screening procedure. After 2 h co-incubation, 
800 μl of the supernatant was aspirated and stored at − 20°C 
before quantification using a GIP ELISA (Millipore, Hert-
fordshire, UK) as per manufacturer’s protocol.
Glucose uptake study using differentiated 
adipocytes
Adipocyte (3T3-L1) cells were obtained from the American 
Type Culture Collection (ATCC, Manassas, Virginia, USA). 
3T3-L1 cells were seeded in a 96, black-walled, clear bottom 
plates (2 ×  104 cell/well). Cells were maintained with Dul-
becco’s Modified Eagle’s Medium (DMEM) supplemented 
with 10% (v/v) heat inactivated FBS. Cells were incubated 
for a further 2 days and then differentiated in DMEM con-
taining 10% FBS, 15 μg/mL insulin, 1 μM dexamethasone 
and 0.5 mM 3-isobutyl-l-methylxanthine (IBMX). Cells 
were cultured in DMEM containing 10% FBS and 15 μg/mL 
of insulin. Cells were treated with the test sample (100 µl) 
or control which were supplemented in glucose-free culture 
medium containing 150 µg/ml fluorescently tagged 2-deox-
yglucose analogue (2-NBDG) and incubated for 20 min. 
Plates were centrifuged for 5 min at 400 × G at RT. Super-
natant was aspirated, and cells washed with 200 µl cell-based 
assay buffer followed by further centrifugation for 5 min. 
Wash buffer was removed and 100 µl of cell-based assay 
buffer was added to all wells and the fluorescence was read 
immediately at 485 nm with emission measured at 535 nm 
using the FlexStation scanning fluorimeter (Molecular 
Devices, Sunnyvale, CA, USA).
Mechanistic studies using BRIN‑BD11 cells
Effect of PPPH’s (2.5 mg/ml) on changes in membrane 
potential and intracellular calcium concentration  [Ca2+] were 
determined fluorometrically utilising monolayers of BRIN-
BD11 cells and Flex membrane potential and calcium assay 
kits (Molecular Devices, Sunnyvale, CA, USA), as previ-
ously described [44]. Assay choice was based on the knowl-
edge that increased intracellular  [Ca2+] is the primary insulin 
secretory signal, while cAMP signalling-dependent mecha-
nisms are also critical for incretin-mediated insulin release 
[61]. Control cultures were 30 mM KCl and 10 mM alanine 
in the presence of 5.6 mM glucose. Fluorometric data were 
acquired using a FlexStation scanning fluorimeter utilizing 
an integrated fluid transfer workstation (Molecular Devices, 
Sunnyvale, CA, USA). The effect of the PPPH’s subjected 
to SGID on the production of cAMP was also assessed in 
BRIN-BD11 cells. Cells were seeded (1.5 ×  105 cells/well) 
into 24-well plates and incubated overnight. Cells were 
washed with HBSS before incubation (20 min, 37°C) with 
the PPPH (2.5 mg/ml) in the presence of 200 μM IBMX. 
Culture media was removed, cells lysed and the cAMP con-
centration in lysates was determined using a cAMP detection 
kit (R&D Systems Parameter, Abingdon, UK).
Acute in vivo effects of a PPPH on glucose tolerance 
and satiety
NIH Swiss mice (Harlan UK Ltd., Blackthorne, UK) 
were employed for acute in vivo experiments. Animals 
(10–12 week old) were maintained in an environmentally 
controlled laboratory at 22 ± 2°C with a 12 h dark and light 
cycle with ad libitum access to standard rodent diet (10% 
fat, 30% protein and 60% carbohydrate: Trouw Nutrition, 
Northwich, UK) and drinking water. Acute glucose-lowering 
and insulin releasing properties of Alcalase/Flavourzyme 
PPPH was determined in age-matched groups (n = 8) of 
overnight-fasted mice, who received an oral gavage of either 
glucose alone (18.8 mmol/kg body weight) or in combina-
tion with PPPH (100 mg/kg bw). Blood glucose was meas-
ured using an Ascencia Contour blood glucose meter (Bayer 
Healthcare, Newbury, UK) and samples were collected via 
tail vein bleed in chilled fluoride/heparin micro-centrifuge 
tubes (Sarstedt, Numbrecht, Germany) and centrifuged at 
13,000 rpm for 10 min. Plasma was aliquoted and stored 
at − 20 °C until required for insulin determination using a 
modified dextran-coated charcoal RIA [40].
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Satiating effect of Alcalase/Flavourzyme PPPH was 
assessed in male HsD:Ola TO mice (10–12 weeks, Envigo, 
Blackthorn, UK), maintained as above. Animals had ad libi-
tum access to food for 1 week. This was reduced to 10 h of 
food availability daily on week 2, with further reduction to 
6 h daily by week 3. Finally, on week 4 and for the duration 
of the satiety studies, food availability was strictly main-
tained at 3 h daily (10.00–13.00 h). Animals (n = 8) received 
an oral dose of saline (0.9% NaCl) alone, or in combination 
with PPPH (100 mg/kg bw) immediately prior to regular 
food access at 10.00 h. Food intake was measured at 30 min 
intervals up to 180 min.
Statistical analysis
Results were analysed using GraphPad PRISM 5.0 (San 
Diego, CA, USA), with data presented as mean ± SEM. 
Comparative analyses between groups were carried out 
using Student’s unpaired t test, one-way ANOVA with a 
Bonferroni post hoc test, or a two-way repeated measures 
ANOVA with a Bonferroni post hoc test where appropriate. 
Results were deemed significant once p < 0.05.
Results
Insulin secretion and cell viability following PPPH 
co‑incubation with BRIN‑BD11 cells
Insulin secretion was determined over a 20 min co-incu-
bation with PPPH supplemented glucose. Baseline insulin 
secretion was established utilising KRBB buffer supple-
mented with basal 5.6 mM or elevated 16.7 mM glucose. 
Several PPPH’s, subjected to different hydrolysis conditions, 
were employed along with SGID equivalents over an iden-
tical concentration range (0.0195–2.5 mg/ml). The aque-
ous/alkaline protein isolate which was subjected to similar 
hydrolysis condition to that of PPPH’s, albeit without the 
addition of enzyme, was employed as a control and elicited 
elevated (p < 0.01—p < 0.001) insulin secretion at 1.25 and 
2.5 mg/ml at basal glucose concentration (Fig. 1a). Interest-
ingly, its SGID equivalent presented with surprisingly high 
insulinotropic activity (p < 0.01-p < 0.001 at > 0.312 mg/
ml) when tested at 16.7  mM glucose concentration in 
BRIN-BD11 cells (Fig. 1b). While potentially anomalous, 



















































































































































































































































































































































































































































































5.6 mM Glucose + PPPH





















5.6 mM Glucose + PPPH SGID
Con Alc AF Brom Prom
Fig. 1  a–k Effects of PPPH (0.0195–2.5  mg/ml) on insulin release 
from clonal pancreatic BRIN-BD11 beta-cells at basal, 5.6 mM, glu-
cose concentration. k Additionally, effects of a fixed (2.5 mg/ml) con-
centration of various protein hydrolysate on cell viability were also 
investigated. Values are mean ± SEM (n = 8). *p < 0.05, **p < 0.01, 
***p < 0.001 compared to control 5.6 mM glucose (a–k). Con: aque-
ous/alkaline control, AF: Alcalase/Flavourzyme, Alc: Alcalase, 
Brom: Bromelain, Prom: Promod
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following SGID, highlights the importance of more com-
plete hydrolysis to the insulinotropic effect.
The inverse was true for PPPH’s. Alcalase PPPH stim-
ulated insulin secretion (p < 0.001) from 0.312 mg/ml and 
above (Fig. 1c). However, following SGID, the effect on 
insulinotropic potency was negatively impacted, with bio-
activity (p < 0.05 to p < 0.01) observed from 1.25 mg/ml 
and above (Fig. 1d). Alteration of the hydrolysis medium 
for Alcalase/Flavourzyme PPPH improved potency, with 
augmented (p < 0.01 to p < 0.001) insulin secretion from 
0.312 mg/ml and above (Fig. 1e). Post-SGID, Alcalase/
Flavourzyme PPPH displayed improved potency, increas-
ing (p < 0.001) insulin secretion at 0.625 mg/ml or above 
(Fig. 1f). Of other digestion conditions, the bromelain 
PPPH exhibited promising insulin secretory actions, with 
improvements (p < 0.05—p < 0.001) compared to base-
line at 0.078 mg/ml or above (Fig. 1g). SGID negatively 
impacted efficacy; however, potency was still impressive, 
enhancing (p < 0.001) insulin secretion from 1.25 mg/ml 
or higher (Fig. 1h). Somewhat unexpectedly, the Pro-
mod PPPH (Fig. 1i) and its SGID equivalent (Fig. 1j) 
displayed bioactivity over an identical concentration 
range (0.625–2.5 mg/ml) with only the magnitude of the 
increased insulin secretion being slightly impacted fol-
lowing SGID.
PPPH’s were further tested in the presence of 16.7 mM 
glucose. While potency was slightly altered, the magni-
tudes and trends involving SGID were largely the same 
for the aqueous, Alcalase, Alcalase/Flavourzyme PPPH’s 
and their SGID counterparts (Fig. 2a–f). The potency of 
both bromelain and Promod PPPH’s at elevated glucose 
was reduced, with respect to the 5.6 mM glucose data, 
but they retained a dose-dependent effect above 0.625 
(Fig. 2g, i). SGID enhanced the potency of these PPPH’s 
in both cases (Fig. 2.H,J). Importantly, when tested at the 
highest concentration, cell viability was not negatively 
impacted by the inclusion of any PPPH at either 5.6 mM 
(Fig. 1k) or 16.7 mM glucose (Fig. 2k).
Preservation of the incretin effect
As shown in Table  1, DPP-4 inhibition significantly 
increased following digestion with all proteolytic enzymes 
employed. Greatest inhibition was observed with PPPH’s 
generated with Alcalase/Flavourzyme or Alcalase 










































































































































































































































































































































































































































16.7 mM Glucose + 1 mM H2O2
















16.7 mM Glucose + PPPH SGID














































Fig. 2   a–k Effects of PPPH (0.0195–2.5 mg/mL) on insulin release 
from clonal pancreatic BRIN-BD11 beta-cells at elevated, 16.7 mM, 
glucose concentration. k Additionally, effects of a fixed (2.5 mg/ml) 
concentration of various protein hydrolysate on cell viability were 
also investigated (K). Values are mean ± SEM (n = 8). **p < 0.01, 
***p < 0.001 compared to control 16.7  mM glucose (a–k). Con: 
aqueous/alkaline control, AF: Alcalase/Flavourzyme, Alc: Alcalase, 
Brom: Bromelain, Prom: Promod
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0.94 ± 0.10 mg/ml, respectively. Bromelain and Promod 
PPPH’s had lower DPP-4 inhibitory activity with  IC50 values 
of 1.34 ± 0.05 and 1.23 ± 0.05 mg/ml, respectively.  IC50 val-
ues of the control and PPPH’s were significantly altered by 
SGID. The DPP-4 inhibitory activity mediated by the con-
trol and bromelain and Promod PPPH’s increased (p < 0.05) 
following SGID. In contrast, the DPP-4 inhibitory activity 
with Alcalase/Flavourzyme and Alcalase PPPH’s decreased 
(p < 0.05) following SGID. Thus, in the latter case peptides 
eliciting high DPP-4 inhibitory activity in the hydrolysate 
were degraded during SGID.
Promotion of the incretin effect
The effects of PPPH upon GLP-1 and GIP secretion was 
investigated via acute exposure of enteroendocrine GLUTag 
and STC-1 cell lines, respectively. Positive controls, glu-
tamine (10 mM), forskolin (10 mM) and GIP  (10–6 M) 
returned from 2- to fourfold (p < 0.05–p < 0.001) increases 
in GLP-1 secretion when compared to basal glucose (2 mM) 
control (Fig. 3a). Likewise, palmitic acid (500 μM) and glu-
tamine (10 mM) showed a fourfold increase (p < 0.001) in 
GIP secretion compared to glucose control (Fig. 3b). PPPH’s 
(2.5 mg/ml) were subsequently co-incubated with 2 mM glu-
cose to investigate their effects on hormone secretion.
The aqueous/alkaline protein control elicited a threefold 
increase (p < 0.001) in GLP-1 secretion compared to basal 
glucose control (Fig. 3a). Following SGID, bioactivity was 
reduced (p < 0.05); however, GLP-1 secretion remained ele-
vated (p < 0.01) versus the 2 mM glucose control (Fig. 3a). 
Interestingly, the inverse was true for GIP secretion, where 
the protein control elicited a fourfold (p < 0.001) increase, 
but the SGID equivalent led to 5.8-fold (p < 0.001) increase 
in GIP secretion compared to glucose control (Fig. 3b). Alca-
lase PPPH displayed a twofold (p < 0.001) increase in GLP-1 
secretion, but post-SGID it failed to raise secretion beyond 
the glucose control (Fig. 3a). For GIP secretion, Alcalase 
PPPH resulted in a sixfold (p < 0.001) increase which was 
improved post-SGID, with an eightfold (p < 0.001) upregula-
tion (Fig. 3b). Little change was observed following addition 
of Flavourzyme, with the hydrolysate promoting a 2.2-fold 
increase in GLP-1 secretion (p < 0.001) accompanied by 
a loss of bioactivity following SGID (Fig. 3a). Unexpect-
edly, GIP secretion was impacted by Alcalase/Flavourzyme 
digestion, whereby the secretory activity was mildly elevated 
(1.2-fold; p < 0.01); however, following SGID, a significant 
reduction (p < 0.01) in secretion was observed (Fig. 3b). 
Bromelain PPPH produced twofold (p < 0.001) rise in 
GLP-1 secretion but only retained a 1.4-fold (p < 0.05) 
secretory response post-SGID (Fig. 3a). Bromelain PPPH 
and its SGID counterpart increased GIP secretion fivefold 
(p < 0.001) and 3.5-fold (p < 0.001), respectively, retaining 
relatively high bioactivity post-SGID (Fig. 3b). The same 
was largely true for Promod PPPH, displaying a 1.6-fold 
(p < 0.001) increase in GLP-1 secretion which was reduced 
Table 1  DPP-4 inhibitory activity of PPPH’s and their SGID equiva-
lents
Mean ± SD (n=3),  IC50: inhibitory concentration that inhibits 
enzyme activity by 50%. *Indicates a significant difference (p< 0.05) 
in  IC50 values following SGID
Proteolytic activity IC50 value (mg/ml)
PPPH PPPH-SGID
Control (none) 1.91 ± 0.10d 1.09 ± 0.06bc,*
Alcalase + Flavourzyme 0.70 ± 0.02a 1.00 ± 0.03bc,*
Alcalase 0.94 ± 0.10b 1.14 ± 0.05c,*
Bromelain 1.34 ± 0.05c 0.95 ± 0.08b,*
Promod 1.23 ± 0.05c 0.78 ± 0.02a,*
A B
Fig. 3  Effects of fixed concentration (2.5  mg/mL) of PPPH on the 
incretin effect through (a) GLP-1 release from GLUTag cells and 
(b) GIP release from STC-1 α-cells. Values are mean ± SEM (n = 4). 
p < 0.05, **p < 0.01, ***p < 0.001 compared to 2  mM glucose con-
trols (a, b). Δp < 0.05, ΔΔp < 0.01, ΔΔΔp < 0.001 compared to the 
appropriate, non-SGID hydrolysate (a, b). Con: aqueous/alkaline 
control, AF: Alcalase/Flavourzyme, Alc: Alcalase, Brom: Bromelain, 
Prom: Promod
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to 1.4-fold (p < 0.05) following SGID (Fig.  3a). Again, 
GIP secretion was relatively well-retained with sixfold 
(p < 0.001) and 3.8-fold (p < 0.001) improvements in hor-
mone secretion beyond control culture for Promod PPPH 
and its SGID equivalent, respectively (Fig. 3b).
Mechanistic consequences of co‑incubation 
with PPPH
The cellular consequences following co-incubation of 
2.5 mg/ml of PPPH were investigated in BRIN-BD11 
cells supplemented with 5.6 mM glucose. Specifically, 
cyclic adenosine monophosphate (cAMP), intracellular 
calcium  ([Ca2+]i) and membrane potential were tested 
under identical conditions. cAMP was initially used to 
screen PPPH’s. The positive controls, 16.7 mM glucose 
and GLP-1  (10–6 M), elevated (p < 0.05 and p < 0.001, 
respectively) intracellular cAMP versus 5.6 mM glucose 
control (Fig. 4a). All six non-SGID, PPPH’s raised cAMP 
production (p < 0.05–p < 0.001) in BRIN-BD11 cells 
(Fig. 4a), while only SGID, Alcalase and SGID, Promod 
PPPH’s failed to stimulate cAMP above the 5.6 mM con-
trol (Fig. 4a). Notably, Alcalase/Flavourzyme PPPH and 
its SGID counterpart, elicited the greatest rise in intracel-
lular cAMP, upregulating 1.7-fold (p < 0.001) compared to 
5.6 mM glucose control (Fig. 4a). As a result of constraints 
over assay availability, combined with the limited avail-
ability of SGID sample, only Alcalase/Flavourzyme PPPH 
was investigated further with respect to cellular signalling.
In terms of intracellular  Ca2+ mobilisation, the posi-
tive control, alanine (10 mM), elicited a 15-fold increase 
(p < 0.001) in calcium mobilisation compared to the 
5.6 mM glucose control culture (Fig. 4b, c). Alcalase/Fla-
vourzyme PPPH greatly surpassed (p < 0.001) the positive 
control, increasing  Ca2+ mobilisation 80-fold (p < 0.001) 
versus the 5.6  mM glucose control (Fig.  4b, c). With 
respect to membrane potential, potassium chloride (KCl, 
30 mM) a potent membrane potentiating insulinotropic 
electrolyte, caused a 75-fold increase (p < 0.001) in mem-
brane potential during acute co-incubation with 5.6 mM 
glucose (Fig. 4d, e). Further to increased  Ca2+, Alcalase/
Flavourzyme PPPH returned a 125-fold peak increase 
(p < 0.001) in membrane potential versus 5.6 mM glucose 
control in BRIN-BD11 cells (Fig. 4d, e).
Effects of PPPH on in vitro glucose uptake
The 3T3-L1 cell line was investigated following trans-
differentiation from fibroblast to adipocyte cells. Apigenin 
control culture evoked a significant reduction (p < 0.001) of 
glucose uptake, via the inhibition of the GLUT-1 receptor, 
with the inverse for low (1 nM) and high (100 nM) insulin, 
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5.6 mM Glucose + 10 mM KCl
5.6 mM Glucose + PPPH - AF
Fig. 4  Mechanistic effects of co-incubation with fixed concentra-
tion (2.5 mg/ml) of PPPH following 20 min incubation with BRIN-
BD11 cells. a PPPH’s and SGID equivalents, were tested for influ-
ence on cAMP concentration, b while only the Alcalase/Flavourzyme 
PPPH (AF) was employed for the study of intracellular calcium 
mobilisation and (d) membrane potential. Respective AUC values 
are also provided (c, e). Values are mean ± SEM (n = 3). *p < 0.05, 
**p < 0.01, ***p < 0.001 compared to 5.6 mM glucose control (a, c, 
e). ΔΔΔp < 0.001 compared to the 10 mM alanine positive control (c, 
e). Con: aqueous/alkaline control, AF: Alcalase/Flavourzyme, Alc: 
Alcalase, Brom: Bromelain, Prom: Promod
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causing 1.4- and 1.8-fold increases (p < 0.001) in glucose 
uptake, respectively (Fig. 5a). All PPPH’s and their SGID 
equivalents, were employed either alone at 2.5 mg/ml or in 
combination with basal insulin (1 nM).
Interestingly, while the protein control failed to show a 
significant increase in glucose on its own, in the presence of 
insulin a 1.5-fold increase (p < 0.05) was observed (Fig. 5b). 
The inverse was true following SGID causing significantly 
increased (p < 0.05) glucose uptake on its own, with surpris-
ing loss of effect in the presence of insulin (Fig. 5b). When 
co-incubated alone, Alcalase PPPH and its SGID equivalent 
both caused comparable, 1.5-fold (p < 0.001), increases in 
glucose uptake; however, when co-incubated with insulin, 
no additive effect was displayed (Fig. 5c). Alcalase/Fla-
vourzyme PPPH, when incubated alone, caused a 1.8-fold 
increase (p < 0.001) in glucose uptake, with co-incubation 
with insulin not impacting greatly, demonstrating a 1.7-fold 
increase (p < 0.001) in uptake (Fig. 5d). Similarly, post-
SGID, elicited a 1.38-fold (p < 0.05) rise in glucose uptake 
both with and without insulin present (Fig. 5d). Bromelain 
PPPH failed to improve glucose uptake when incubated on 
its own, with notable improvement presented as a 1.5-fold 
increase (p < 0.01) following insulin co-incubation (Fig. 5e). 
However, following SGID, the sample failed to produce an 
improvement in glucose uptake in the absence or presence of 
insulin (Fig. 5e). Similarly, Promod PPPH was only effective 
in the presence of insulin, when glucose uptake increased by 
1.5-fold (p < 0.05), but this was lost following SGID, with 
the sample having no effect either alone or in the presence 
of insulin (Fig. 5f).
Acute in vivo effects following oral administration 
of PPPH
Following initial dose–response investigations (see Supple-
mentary Figures), a 100 mg/kg/bw dose of Alcalase/Flavour-
zyme PPPH was employed for in vivo investigations. When 
co-administered with 18.8 mM glucose, PPPH significantly 
curbed rises in blood glucose at 60 min (p < 0.01), as well 
as 90 and 120 min (p < 0.001), when compared to glucose-
only control (Fig. 6a). Additionally, the area under the curve 
(AUC) was significantly reduced (p < 0.01) compared to 
control (Fig. 6b). Positive glycaemic effects appear to be 
relatively short-lasting, with a delayed oral glucose chal-
lenge showing no anti-hyperglycaemic efficacy when deliv-
ered 4, 8 or 12 h post PPPH administration (data not shown).
Additionally, when co-administered with saline, PPPH 
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Prom Prom-SGID
Fig. 5  Effects of PPPH (2.5  mg/ml) on glucose uptake individually, 
or in combination with insulin (1 nM), in trans-differentiated 3T3-L1 
adipocyte cells. Responsiveness of adipocyte cells was assessed via 
incubation with either apigenin (50 μfM), insulin (1 nM or 100 nM) 
(a). Adipocyte cells were further incubated with either Con/Con-
SGID (b), Alc/Alc-SGID (c), AF/AF-SGID (d), Brom/Brom-SGID 
(e) or Prom/Prom-SGID (f) using fixed concentration of hydrolysate 
(2.5 mg/ml) for 1 h with 3 mM fluorescent glucose (2-NBDG). Val-
ues are mean ± SEM (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001 com-
pared to respective glucose control. Con: aqueous/alkaline control, 
AF: Alcalase/Flavourzyme, Alc: Alcalase, Brom: bromelain, Prom: 
Promod
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to p < 0.001) in food intake (16–20% from 90 to 180 min) 
when tested in diet-restricted animals (Fig. 6c).
Discussion
While accepted that an increase in dietary protein intake can 
have positive effects on glycaemic control for T2DM patients 
[10]; expanding population sizes, coupled with pre-existing 
social inequality, continue to drive global protein malnutri-
tion [45–47]. It is predicted that the global human population 
will reach 9 billion by 2050, meaning trends in population 
expansion are unlikely to be curbed. Thus, greater empha-
sis must be placed on ensuring food security [48]. Novel 
sources are being pursued to address this, one such being 
the exploration of marine sources like seaweeds, industry 
off-cuts and underutilised, or low value fish species, many of 
which are currently used as animal and farmed fish/shellfish 
feed [31, 49, 50]. Algal proteins are of particular interest due 
to a favourable amino acid composition, containing all nine 
essential amino acids [51], combined with a relatively high 
protein content, particularly for red seaweeds which often 
contain ≥ 30% of protein by dry weight [52].
It was recently established that chronic administration 
of an Alcalase/Flavourzyme PPPH can improve glycaemic 
control in STZ-induced diabetic mice [34]. Therefore, uti-
lising an array of in vitro and acute in vivo techniques, the 
present study aimed to uncover causative mechanisms of 
PPPH-induced benefits in diabetes, investigating Alcalase/
Flavourzyme PPPH while taking the opportunity to compare 
it to a number of other enzymatically produced PPPH’s.
Initial screening involved assessment of insulinotropic 
activity of PPPH’s in BRIN-BD11 cells, which have been 
previously utilised in the screening of enzymatically pro-
duced protein hydrolysates [25–27]. We hypothesised that 
activity would rely on the hydrolysis process, specifically the 
duration of hydrolysis and the protease used, ultimately lead-
ing to a different range of bioactive peptides within crude 
mixtures [53]. Our data appear to support this, particularly 
with respect to the choice of enzyme and the extent to which 
it hydrolyses P. palmata proteins and the MW of peptides 
therein. As reflected in the molecular distribution profiles 
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Fig. 6  a, b Effects of a fixed dose (100  mg/kg/bw) of Alcalase/
Flavourzyme PPPH (AF) on glucose tolerance in lean, overnight-
fasted (16  h) NIH Swiss mice and (c) acute food intake in lean, 
diet-restricted HsD:Ola T0 mice. Animals (n = 8) received glucose 
(18.8 mmol/kg/bw) alone or in combination with hydrolysate (a) or 
saline (0.9% NaCl) alone or in combination with hydrolysate via oral 
gavage (c). Measurements were taken at regular intervals as indi-
cated (a, c). Values are mean ± SEM (n = 8). *p < 0.05, **p < 0.01, 
***p < 0.001 compared to glucose only (a, b) or saline only (c) con-
trols
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profiles (Supplementary Fig. 4), both Alcalase and Alca-
lase/Flavourzyme mediated a higher extent of hydrolysis 
of P. palmata proteins than bromelain and Promod. Also, 
all hydrolysates were further hydrolysed during the in vitro 
digestion process, which had either a positive or negative 
impact on bioactivity.
Insulinotropic effects of the protein control, were vastly 
improved following SGID, while the insulinotropic potency 
of Alcalase and Alcalase/Flavourzyme PPPH’s subjected to 
SGID was reduced rather than totally abolished, an encour-
aging finding. Intriguingly, particularly at 16.7 mM glu-
cose, bromelain and Promod PPPH’s showed unaltered or 
even improved bioactivity post-SGID. Further analysis may 
uncover the possibility that glycation of specific compo-
nents can affect their bioactivity, with the data suggesting 
that, for most PPPH’s, the potency of insulinotropic effect 
was greater at 16.7 mM than at 5.6 mM glucose. Given 
insulinotropic peptides, such as GIP, are demonstrated to 
have improved bioactivity following N-terminal glycation 
[54, 55], this may be plausible, but remains a hypothesis. 
Furthermore, the favourable MTT data showing no cellular 
cytotoxicity, demonstrated that the increased insulin release 
induced by PPPH was not a result of beta-cell lysis [56].
It is well established that both crude hydrolysates [32], 
and isolated peptide sequences [33], derived from P. pal-
mata, have excellent DPP-4 inhibitory properties. As such, 
for the present set of PPPH’s, these findings have been cor-
roborated. Furthermore, the effects were largely retained or 
even improved upon following SGID, indicating extensive 
oral bioavailability [25, 27]. While likely a less important 
factor in in vitro insulin secretion than in in vivo scenarios, 
previously identified presence of intra-islet DPP-4 [72], as 
well as expression within beta-cells themselves [73], means 
the influence of DPP-4 inhibitory effects to the insulino-
tropic effects of PPPH’s cannot be completely ruled out, but 
certainly warrant further investigation. The clinical success 
of DPP-4 inhibition is mediated through preservation of the 
incretin effect, and this mechanism is well established in 
management of T2DM [23, 57–59]. The present data demon-
strates that: beyond preservation of the incretin effect, crude 
PPPH’s can directly influence incretin-mediated glycaemic 
improvements via the stimulation of GLP-1 and GIP secre-
tion [60]. Thus, all PPPH’s enhanced both in vitro GLP-1 
and GIP secretion in their unaltered states, a finding sup-
ported by previous findings of marine protein-hydrolysate-
induced GLP-1 secretion [25, 27]. Intriguingly, the effects 
on GIP secretion were more resistant to SGID than those of 
GLP-1, with the effect at least retained for every hydrolysate 
except Alcalase/Flavourzyme PPPH. It is important to note 
that, given the crude nature of the hydrolysate mixtures, dif-
fering small MW peptides or free amino acid components 
may be responsible for each effect.
In vitro analysis of mechanistic consequences of PPPH 
co-incubation further highlights the ability of PPPH to 
influence insulin release. Membrane depolarisation, cal-
cium mobilisation and generation of cAMP were employed 
to provide a general overview of activity. As such, cAMP 
upregulation suggests that small MW peptides may be stimu-
lating secretion of hormones such as insulin, GLP-1 and GIP 
via G-coupled protein receptor activation [61]. These recep-
tors are only activated by extracellular stimuli and can have 
potent cellular activation via promotion of internal signalling 
cascades [62, 63]. For example, activation of the GLP-1r via 
GLP-1 promotes a significant increase in cAMP production 
and glucose-dependent insulin secretion [63]. Indeed, each 
PPPH elicited cAMP elevation beyond baseline, with vary-
ing degrees of effect. In particular, Alcalase/Flavourzyme 
PPPH exhibited the most potent elevation, with full reten-
tion following SGID. Furthermore, this hydrolysate greatly 
influenced both membrane depolarisation and calcium mobi-
lisation, beyond positive controls. While the direct effects on 
intracellular signalling appear to be multifaceted [62–64], 
further investigation is required to identify whether the 
bioactivity emanates from a potent singular peptide entity 
within the crude mixture, or if it arises from synergistic 
mechanisms of various peptides or amino acids [65].
3T3-L1 adipocyte cells were utilised to examine the 
ability of the PPPH and SGID samples to stimulate glucose 
uptake. These cells exhibit all the components of insulin 
receptor and signal transduction cascade and are frequently 
used to investigate insulin mediated glucose transport [66]. 
It is believed that compensatory upregulation of insulin pro-
duction and secretion can result in impaired glucose trans-
port into liver, skeletal muscle, and adipose tissue in T2DM 
[67]. Furthermore, it is postulated that dysfunctional periph-
eral glucose uptake, may contribute to insulin resistance in 
skeletal muscle [68]. The present data unveils a positive role 
for PPPH in glucose transport, with Alcalase and Alcalase/
Flavourzyme PPPH’s increasing glucose uptake, independ-
ent of insulin, with the effect partially surviving SGID. Such 
findings may be related to the acute glucose tolerance test 
data. Thus, oral administration of Alcalase/Flavourzyme 
PPPH improved the oral glucose tolerance significantly from 
60 min onwards of challenge initiation. While thought to 
be multifactorial in nature, improved glucose uptake could 
be a contributing factor [69]. Insulin determination was not 
possible during these experiments; however, previous find-
ings have demonstrated that chronic administration of an 
equivalent dose of this hydrolysate (split into twice daily 
50 mg/kg/bw dosage) improved non-fasting insulin levels, 
with accompanying improvements in circulating glucose 
and  HbA1c, over the treatment period [34]. Additionally, 
we highlight a role for PPPH administration in satiety, with 
notable reduction from baseline evident from 90 to 180 min 
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inclusive when tested in food deprived trained mice, again 
supported by previous findings [34].
Taken together, this dataset fortifies interest in PPPH with 
regards to management of T2DM. Knowledge of the previ-
ously established roles in DPP-4 inhibition [32] and partial 
reversal of STZ-induced diabetes [34] have been expanded 
upon. Here, we show clear roles for PPPH in direct insu-
lin and incretin secretion, supported by cellular signalling 
data, as well as improvements in glucose utilisation and 
tolerance now identified. It is now accepted that particular 
combinations of individual amino acids, such as leucine, 
alanine and glutamine, at supraphysiological concentrations 
can augment insulin secretion [61]. We postulate that such 
a mechanism may be at play here with crude hydrolysate 
mixtures, thus future work may isolate, identify and charac-
terise specific peptides, single amino acids or combinations 
thereof, small molecules or lipids from the most consistently 
promising of the hydrolysates, Alcalase/Flavourzyme PPPH 
[33]. The latter hydrolysate was particularly promising given 
its direct insulinotropic effects, accompanied by promising 
effects on the intracellular mechanisms linked to insulin 
release, along with positive effects on glucose uptake.
The study possesses some limitations, primarily that 
limited SGID sample availability did not permit inclusion 
of all test hydrolysates in our mechanistic investigations. 
In the present preliminary study, the findings observed 
herein on glycaemic control and insulin secretion could 
arise due to multiple different actions mediated by the 
PPPH peptides. These might involve for example, the 
inhibition of DPP-4 prolonging the bioactivity of GLP-1 
and GIP incretin hormones or insulinotropic actions of 
free amino acids. However, extensive detailed mechanistic 
studies would be required to elucidate the various mecha-
nisms, which is beyond the scope of the current study. 
Furthermore, a chronic study with isolated peptides would 
be warranted to increase our knowledge on the bioactivity 
residing in PPPH. Additionally, given all the hydrolysates 
assessed herein inhibit angiotensin converting enzyme 
(ACE) (data not shown) combined with our clearly iden-
tified effects on satiety, it may be interesting to investigate 
the influence PPPH can play on regulation of satiating hor-
mones like cholecystokinin (CCK) and PYY(3–36), both 
of which are substrates for ACE [70, 71].
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